AERI Pengajuan SEC - Aerie Pharmaceuticals Inc- Laporan Tahunan, Pernyataan Kuasa, Prospektus

Mga Batayang Estadistika

LEI	529900SFXHDHUO324R09
CIK	1337553

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Aerie Pharmaceuticals Inc

SEC Filings (Chronological Order)

Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.

February 10, 2023	SC 13G/A	AERI / Aerie Pharmaceuticals Inc / Flynn James E Passive Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No.
December 1, 2022	15-12G	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File No. 001-36152 Aerie Pharmaceuticals, Inc. (Exact name of registrant as specified in
November 21, 2022	S-8 POS	As filed with the Securities and Exchange Commission on November 21, 2022 As filed with the Securities and Exchange Commission on November 21, 2022 Registration No.
November 21, 2022	EX-3.1	AMENDED AND RESTATED CERTIFICATE OF INCORPORATION AERIE PHARMACEUTICALS, INC. ARTICLE ONE Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF AERIE PHARMACEUTICALS, INC. ARTICLE ONE The name of the corporation is Aerie Pharmaceuticals, Inc. (the “Corporation”). ARTICLE TWO The address of the Corporation’s registered office in the State of Delaware is 251 Little Falls Drive, Wilmington, County of New Castle, 19808. The name of its registered agent at such address is Corpora
November 21, 2022	S-8 POS	As filed with the Securities and Exchange Commission on November 21, 2022 As filed with the Securities and Exchange Commission on November 21, 2022 Registration No.
November 21, 2022	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 21, 2022 Aerie Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36152 20-3109565 (State or other jurisdiction of incorporation) (Comm
November 21, 2022	S-8 POS	As filed with the Securities and Exchange Commission on November 21, 2022 As filed with the Securities and Exchange Commission on November 21, 2022 Registration No.
November 21, 2022	S-8 POS	As filed with the Securities and Exchange Commission on November 21, 2022 As filed with the Securities and Exchange Commission on November 21, 2022 Registration No.
November 21, 2022	S-8 POS	As filed with the Securities and Exchange Commission on November 21, 2022 As filed with the Securities and Exchange Commission on November 21, 2022 Registration No.
November 21, 2022	EX-3.2	AMENDED AND RESTATED BY-LAWS Aerie Pharmaceuticals, Inc. As adopted as of November 21, 2022 AERIE PHARMACEUTICALS, INC. A Delaware Corporation Exhibit 3.2 AMENDED AND RESTATED BY-LAWS of Aerie Pharmaceuticals, Inc. As adopted as of November 21, 2022 AERIE PHARMACEUTICALS, INC. A Delaware Corporation AMENDED AND RESTATED BY-LAWS ARTICLE I STOCKHOLDERS 1. Annual Meeting. Unless directors are elected by written consent in lieu of an annual meeting, an annual meeting of stockholders for the purposes of electing directors and of transacting s
November 21, 2022	S-8 POS	As filed with the Securities and Exchange Commission on November 21, 2022 As filed with the Securities and Exchange Commission on November 21, 2022 Registration No.
November 21, 2022	S-8 POS	As filed with the Securities and Exchange Commission on November 21, 2022 As filed with the Securities and Exchange Commission on November 21, 2022 Registration No.
November 21, 2022	EX-4.1	AERIE PHARMACEUTICALS, INC. WILMINGTON TRUST, NATIONAL ASSOCIATION, as Trustee FIRST SUPPLEMENTAL INDENTURE dated as of November 21, 2022 to the dated as of September 9, 2019 1.50% Convertible Senior Notes due 2024 Exhibit 4.1 Execution Version AERIE PHARMACEUTICALS, INC. and WILMINGTON TRUST, NATIONAL ASSOCIATION, as Trustee FIRST SUPPLEMENTAL INDENTURE dated as of November 21, 2022 to the INDENTURE dated as of September 9, 2019 1.50% Convertible Senior Notes due 2024 FIRST SUPPLEMENTAL INDENTURE (this “Supplemental Indenture”), dated as of November 21, 2022, between Aerie Pharmaceuticals, Inc., a Delaware
November 21, 2022	S-8 POS	As filed with the Securities and Exchange Commission on November 21, 2022 S-8 POS 1 brhc10044429s8pos.htm S-8 POS As filed with the Securities and Exchange Commission on November 21, 2022 Registration No. 333-216578 Registration No. 333-219671 Registration No. 333-221442 Registration No. 333-223364 Registration No. 333-263504 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Post-Effective Amendment No. 1 to: Form S-8 Registration Statement No. 333
November 18, 2022	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 17, 2022 Aerie Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36152 20-3109565 (State or other jurisdiction of incorporation) (Comm
November 7, 2022	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2022 Aerie Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36152 20-3109565 (State or other jurisdiction of incorporation) (Commi
November 7, 2022	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defini
November 4, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-3615
November 3, 2022	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 1, 2022 Aerie Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36152 20-3109565 (State or other jurisdiction of incorporation) (Commi
November 3, 2022	EX-99.1	Aerie Pharmaceuticals Reports Third Quarter 2022 Financial Results Third Quarter Glaucoma Franchise Net Revenues of $36.1 Million, up 23% over Third Quarter 2021 Previously Announced Agreement to be Acquired by Alcon; Transaction Expected to Close in Exhibit 99.1 Aerie Pharmaceuticals Reports Third Quarter 2022 Financial Results Third Quarter Glaucoma Franchise Net Revenues of $36.1 Million, up 23% over Third Quarter 2021 Previously Announced Agreement to be Acquired by Alcon; Transaction Expected to Close in the Fourth Quarter of 2022 Durham, North Carolina, November 3, 2022 ? (BUSINESS WIRE) ? Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), a ph
October 7, 2022	DEFM14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? ? ? Filed by a party other than the Registrant ?? ? ? Check the appropriate box: ?? Preliminary Proxy Statement ?? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)
September 21, 2022	EX-FILING FEES	CALCULATION OF FILING FEE TABLES Schedule 14A (Form Type) Aerie Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Transaction Valuation Exhibit 107 CALCULATION OF FILING FEE TABLES Schedule 14A (Form Type) Aerie Pharmaceuticals, Inc.
September 21, 2022	PREM14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? ? ? Filed by a party other than the Registrant ?? ? ? Check the appropriate box: ? Preliminary Proxy Statement ?? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(
September 13, 2022	EX-99.1	Disclaimer The information in this presentation regarding Aerie Pharmaceuticals, Inc. (the “Company” or “Aerie”) does not contain all of the information that a potential investor should review before investing in Aerie shares. The descriptions of Aer Exhibit 99.1 AERIE An Emerging Leader in Ophthalmology September 2022 For Investor Use Only 1 Disclaimer The information in this presentation regarding Aerie Pharmaceuticals, Inc. (the ?Company? or ?Aerie?) does not contain all of the information that a potential investor should review before investing in Aerie shares. The descriptions of Aerie in this presentation are qualified in their entirety
September 13, 2022	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 13, 2022 Aerie Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36152 20-3109565 (State or other jurisdiction of incorporation) (Com
August 23, 2022	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 22, 2022 Aerie Pharmaceuti UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 22, 2022 Aerie Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36152 20-3109565 (State or other jurisdiction of incorporation) (Commis
August 23, 2022	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin
August 23, 2022	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 22, 2022 Aerie Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36152 20-3109565 (State or other jurisdiction of incorporation) (Commis
August 23, 2022	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 22, 2022 Aerie Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36152 20-3109565 (State or other jurisdiction of incorporation) (Commis
August 23, 2022	EX-99.1	1 Exhibit 99.1 MEDIA RELEASE ? COMMUNIQUE AUX MEDIAS ? MEDIENMITTEILUNG Alcon to Acquire Aerie Pharmaceuticals, Inc., Enhancing its Ophthalmic Pharmaceutical Portfolio ? Builds on Alcon?s existing commercial expertise in the estimated $20 billion global ophthalmic pharmaceutical segment1 ? Adds Rocklatan? and Rhopressa?, and a pipeline of several clinical and preclinical ophthalmic pharmaceutical pr
August 23, 2022	EX-2.1	Agreement and Plan of Merger, dated as of August 22, 2022, by and among the Company, Exhibit 2.1 AGREEMENT AND PLAN OF MERGER among AERIE PHARMACEUTICALS, INC., a Delaware corporation, ALCON RESEARCH, LLC, a Delaware limited liability company, and LYON MERGER SUB, INC., a Delaware corporation, Dated as of August 22, 2022 Table of Contents Section 1 The Merger 1.1 The Closing 1 1.2 The Merger 2 1.3 Conversion of Shares 2 1.4 Surrender of Certificates; Stock Transfer Books 3 1.5 Dis
August 23, 2022	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 22, 2022 Aerie Pharmaceuti UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 22, 2022 Aerie Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36152 20-3109565 (State or other jurisdiction of incorporation) (Commis
August 5, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36152 Aer
August 5, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2022 Aerie Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36152 20-3109565 (State or other jurisdiction of incorporation) (Commiss
August 5, 2022	EX-99.1	Aerie Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update Second Quarter Glaucoma Franchise Net Revenues of $33.3 Million, up 23% over Second Quarter 2021 Outlook for Net Cash Used Expected to Be Less Than $20 M Exhibit 99.1 Aerie Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update Second Quarter Glaucoma Franchise Net Revenues of $33.3 Million, up 23% over Second Quarter 2021 Outlook for Net Cash Used Expected to Be Less Than $20 Million per Quarter, on Average, for the Remainder of 2022 Aerie Expects to be Cash Flow Break Even During 2024 Durham, North Carolina, Au
August 1, 2022	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 1, 2022 Aerie Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36152 20-3109565 (State or other jurisdiction of incorporation) (Commiss
August 1, 2022	EX-99.1	Aerie Pharmaceuticals Announces First Participant Dosed in the COMET-3 Study of AR-15512 for the Treatment of Dry Eye Disease AR-15512 is a differentiated, novel, first-in-class product candidate for the treatment of the signs and symptoms of Dry Eye Exhibit 99.1 Aerie Pharmaceuticals Announces First Participant Dosed in the COMET-3 Study of AR-15512 for the Treatment of Dry Eye Disease AR-15512 is a differentiated, novel, first-in-class product candidate for the treatment of the signs and symptoms of Dry Eye Disease COMET-3 is the second of three studies in the AR-15512 Registrational Phase 3 Program Durham, N.C. ? (BUSINESS WIRE) ? August 1,
June 13, 2022	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 9, 2022 Aerie Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36152 20-3109565 (State or other jurisdiction of incorporation) (Commissio
June 8, 2022	EX-99.1	Disclaimer The information in this presentation regarding Aerie Pharmaceuticals, Inc. (the “Company” or “Aerie”) does not contain all of the information that a potential investor should review before investing in Aerie shares. The descriptions of Aer EX-99.1 Exhibit 99.1 AERIE An Emerging Leader in Ophthalmology Ju n e 2 0 2 2 For Investor Use Only 1 Disclaimer The information in this presentation regarding Aerie Pharmaceuticals, Inc. (the “Company” or “Aerie”) does not contain all of the information that a potential investor should review before investing in Aerie shares. The descriptions of Aerie in this presentation are qualified in their e
June 8, 2022	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 8, 2022 Aerie Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36152 20-3109565 (State or other jurisdiction of incorporation) (Commissio
May 25, 2022	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 25, 2022 Aerie Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36152 20-3109565 (State or other jurisdiction of incorporation) (Commissio
May 25, 2022	EX-99.1	Disclaimer The information in this presentation regarding Aerie Pharmaceuticals, Inc. (the “Company” or “Aerie”) does not contain all of the information that a potential investor should review before investing in Aerie shares. The descriptions of Aer Exhibit 99.1 AERIE An Emerging Leader in Ophthalmology Ma y 2 0 2 2 For Investor Use Only 1 Disclaimer The information in this presentation regarding Aerie Pharmaceuticals, Inc. (the ?Company? or ?Aerie?) does not contain all of the information that a potential investor should review before investing in Aerie shares. The descriptions of Aerie in this presentation are qualified in their entirety by
May 24, 2022	EX-99.1	Aerie Pharmaceuticals Announces First Participant Dosed in the Phase 3 Registrational COMET-2 Study of AR-15512 for the Treatment of Dry Eye Disease AR-15512 is a differentiated, novel, first-in-class product candidate for the treatment of the signs Exhibit 99.1 Aerie Pharmaceuticals Announces First Participant Dosed in the Phase 3 Registrational COMET-2 Study of AR-15512 for the Treatment of Dry Eye Disease AR-15512 is a differentiated, novel, first-in-class product candidate for the treatment of the signs and symptoms of Dry Eye Disease COMET-2 is the first of three studies in the AR-15512 Phase 3 Program Durham, N.C. ? (BUSINESS WIRE) ? Ma
May 24, 2022	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 24, 2022 Aerie Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36152 20-3109565 (State or other jurisdiction of incorporation) (Commissio
May 6, 2022	EX-10.3	Aerie Pharmaceuticals, Inc. Nonqualified Deferred Compensation Plan and Adoption Agreement. NOLAN FINANCIAL FORM NONQUALIFIED DEFERRED COMPENSATION PLAN ADOPTION AGREEMENT NONQUALIFIED DEFERRED COMPENSATION PLAN The undersigned Company acting on behalf of itself and each Participating Employer, having been duly advised by its own counsel as to the legal and tax consequences of adopting this Nonqualified Deferred Compensation Plan (the ?Plan?) and having determined that adoption of this u
May 6, 2022	EX-10.1	by and between Aerie Pharmaceuticals, Inc. and The XXXXXXXXXXXXX denotes information that has been redacted. EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (the ?Agreement?) made this 18th day of March 2022 (the ?Effective Date?) is by and between Aerie Pharmaceuticals, Inc., a Delaware corporation with principal executive offices at 4301 Emperor Blvd. Suite 400 Durham, NC 27703 (the ?Company?), and Peter Lang residing at XXXXXXXXXXXXXXX (?Exe
May 6, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36152 Ae
May 6, 2022	EX-10.2	Renewal to the Manufacture and Supply Agreement, dated as of January 3, 2022, by and between Cayman Chemical Company, Incorporated and Aerie Distribution, Incorporated. The XXXCERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED.
May 5, 2022	EX-99.1	Aerie Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Update First Quarter Glaucoma Franchise Net Revenues of $29.8 Million, up 30% over First Quarter 2021 Management Reaffirms 2022 Glaucoma Franchise Guidance of $1 Exhibit 99.1 Aerie Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Update First Quarter Glaucoma Franchise Net Revenues of $29.8 Million, up 30% over First Quarter 2021 Management Reaffirms 2022 Glaucoma Franchise Guidance of $130 Million to $140 Million First Phase 3 Registrational Trial for AR-15512 On-Track for Enrollment Second Quarter of 2022 Durham, North C
May 5, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2022 Aerie Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36152 20-3109565 (State or other jurisdiction of incorporation) (Commission
April 26, 2022	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin
April 26, 2022	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin
April 11, 2022	EX-99.1	Disclaimer The information in this presentation regarding Aerie Pharmaceuticals, Inc. (the “Company” or “Aerie”) does not contain all of the information that a potential investor should review before investing in Aerie shares. The descriptions of Aer EX-99.1 Exhibit 99.1 AERIE An Emerging Leader in Ophthalmology Ap r i l 2 0 2 2 For Investor Use Only 1 Disclaimer The information in this presentation regarding Aerie Pharmaceuticals, Inc. (the “Company” or “Aerie”) does not contain all of the information that a potential investor should review before investing in Aerie shares. The descriptions of Aerie in this presentation are qualified in their
April 11, 2022	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 11, 2022 Aerie Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36152 20-3109565 (State or other jurisdiction of incorporation) (Commiss
March 18, 2022	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 15, 2022 Aerie Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36152 20-3109565 (State or other jurisdiction of incorporation) (Commiss
March 18, 2022	EX-99.1	Aerie Pharmaceuticals Appoints Peter Lang as Chief Financial Officer Finance executive with a successful track record in capital creation, deployment, and optimization Brings breadth of finance, strategy and business development experience Exhibit 99.1 Aerie Pharmaceuticals Appoints Peter Lang as Chief Financial Officer Finance executive with a successful track record in capital creation, deployment, and optimization Brings breadth of finance, strategy and business development experience Durham, N.C. ? (BUSINESS WIRE) ? March 18, 2022 ? Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), a pharmaceutical company focused on the discovery, de
March 11, 2022	EX-4.4	Second Amendment to the Aerie Pharmaceuticals, Inc. Second Amended and Restated Inducement Award Plan. Exhibit 4.4 SECOND AMENDMENT OF THE AERIE PHARMACEUTICALS, INC. SECOND AMENDED & RESTATED INDUCEMENT AWARD PLAN THIS SECOND AMENDMENT of the Aerie Pharmaceuticals, Inc. Second Amended & Restated Inducement Award Plan is dated as of March 11, 2022. WHEREAS, the Board of Directors of Aerie Pharmaceuticals, Inc. (the ?Company?) has adopted the Aerie Pharmaceuticals, Inc. Second Amended & Restated Ind
March 11, 2022	S-8	As filed with the Securities and Exchange Commission on March 11, 2022 As filed with the Securities and Exchange Commission on March 11, 2022 Registration No.
March 11, 2022	EX-FILING FEES	Filing Fee Tables. EX-FILING FEES 5 d269554dexfilingfees.htm EX-FILING FEES Exhibit 107.1 Calculation of Filing Fee Tables Form S-8 (Form Type) Aerie Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule(3) Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price F
March 4, 2022	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 1, 2022 Aerie Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36152 20-3109565 (State or other jurisdiction of incorporation) (Commissi
March 2, 2022	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 1, 2022 Aerie Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36152 20-3109565 (State or other jurisdiction of incorporation) (Commissi
February 25, 2022	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36152 Aerie Pharmaceuticals, Inc.
February 25, 2022	EX-10.36	Employment Agreement, dated as of December 15, 2021, by and between Aerie Pharmaceuticals, Inc. and Raj Kannan. Exhibit 10.36 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. [***] INDICATES THAT INFORMATION HAS BEEN REDACTED. EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (the ?Agreement?) made this 15th day of December, 2021 (the ?Effective Date?) is by and between Aerie Pharma
February 25, 2022	EX-10.35	Collaboration and License Agreement, dated as of December 6, 2021, by and between Aerie Pharmaceuticals Ireland, Ltd. and Santen SA. Exhibit 10.35 INFORMATION IN THIS AGREEMENT IDENTIFIED BY ?[***]? IS CONFIDENTIAL AND HAS BEEN EXCLUDED PURSUANT TO ITEM 601(b)(10)(iv) OF REGULATION S-K BECAUSE IT (I) IS NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. COLLABORATION AND LICENSE AGREEMENT by and between AERIE PHARMACEUTICALS IRELAND, LTD. and SANTEN SA Dated as of December 6, 2021
February 25, 2022	EX-10.29	Third Amendment to Contract Manufacturing Supply Agreement, dated as of January 1, 2020, by and between Bausch & Lomb Incorporated, Aerie Pharmaceuticals, Inc. and Aerie Distribution Incorporated. Exhibit 10.29 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. [***] INDICATES THAT INFORMATION HAS BEEN REDACTED. THIRD AMENDMENT TO CONTRACT MANUFACTURING SUPPLY AGREEMENT This Third Amendment (this "Amendment") to Contract Manufacturing Supply Agreement is entered in
February 25, 2022	EX-10.40	Form of Aerie Pharmaceuticals, Inc. Inducement Award Plan Restricted Stock Agreement Exhibit 10.40 AERIE PHARMACEUTICALS, INC. AMENDED & RESTATED OMNIBUS INCENTIVE PLAN FORM OF RESTRICTED STOCK AGREEMENT THIS AGREEMENT (this ?Agreement?) effective as of the date of grant set forth on the signature page hereto (the ?Date of Grant?), is between Aerie Pharmaceuticals, Inc., a Delaware corporation (together with its successors, the ?Company?), and the individual whose name is set fort
February 25, 2022	EX-10.39	Form of Aerie Pharmaceuticals, Inc. Inducement Award Plan Incentive Stock Option Agreement (Benjamin F. McGraw, III, Pharm.D.). Exhibit 10.39 FORM OF INCENTIVE STOCK OPTION AGREEMENT Aerie Pharmaceuticals, Inc., a Delaware corporation (the ?Company?), hereby grants to the individual named below an option (the ?Option?) to purchase certain shares of common stock of the Company pursuant to the Aerie Pharmaceuticals, Inc. 2013 Omnibus Incentive Plan, in the manner and subject to the provisions of this Option Agreement. Except
February 25, 2022	EX-10.37	Form of Aerie Pharmaceuticals, Inc. Inducement Award Plan Nonqualified Stock Option Agreement (Raj Kannan). Exhibit 10.37 FORM OF NON-QUALIFIED STOCK OPTION AGREEMENT Aerie Pharmaceuticals, Inc., a Delaware corporation (the ?Company?), hereby grants to the individual named below an option (the ?Option?) to purchase certain shares of common stock of the Company pursuant to the Aerie Pharmaceuticals, Inc. Inducement Award Plan, in the manner and subject to the provisions of this Option Agreement. Except a
February 25, 2022	EX-10.38	Form of Aerie Pharmaceuticals, Inc. Inducement Award Plan Restricted Stock Agreement (Raj Kannan). Exhibit 10.38 AERIE PHARMACEUTICALS, INC. INDUCEMENT AWARD PLAN FORM OF RESTRICTED STOCK AGREEMENT THIS AGREEMENT (this ?Agreement?) effective as of the date of grant set forth on the signature page hereto (the ?Date of Grant?), is between Aerie Pharmaceuticals, Inc., a Delaware corporation (together with its successors, the ?Company?), and the individual whose name is set forth on the signature p
February 25, 2022	EX-4.3	Description of the Registrant's Securities. Exhibit 4.3 Description of Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934 As of December 31, 2021, Aerie Pharmaceuticals, Inc., a Delaware corporation, had one class of securities registered under Section 12 of the Securities Exchange Act of 1934 (the ?Exchange Act?): Common Stock, par value $0.001 per share (the ?Common Stock?). The following summary includes
February 24, 2022	EX-99.1	Aerie Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update 2021 Glaucoma Franchise Net Revenues of $112.1 Million, an Increase of 35% over 2020 Fourth Quarter Glaucoma Franchise Net Revenues of $32. EX-99.1 2 aeri-4q21earningsreleaseex.htm EX-99.1 Exhibit 99.1 Aerie Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update 2021 Glaucoma Franchise Net Revenues of $112.1 Million, an Increase of 35% over 2020 Fourth Quarter Glaucoma Franchise Net Revenues of $32.7 Million, up 11% From Third Quarter Guidance of $130 Million to $140 Million in 2022 Gl
February 24, 2022	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 17, 2022 Aerie Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36152 20-3109565 (State or other jurisdiction of incorporation) (Comm
February 14, 2022	SC 13G/A	AERI / Aerie Pharmaceuticals Inc / PFM Health Sciences, LP - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) Information Statement Pursuant to Rules 13d-1 and 13d-2 Under the Securities Exchange Act of 1934 (Amendment No. 3 )* Aerie Pharmaceuticals, Inc. (Name of Issuer) Common stock, par value $0.001 per share (Title of Class of Securities) 00771V108 (CUSIP Number) December 31, 2021 Date of Event Which Re
February 14, 2022	EX-99.1	JOINT FILING AGREEMENT EX-99.1 2 tm225765d5ex99-1.htm JOINT FILING AGREEMENT EXHIBIT 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on Schedule 13G/A filed herewith (and any amendments thereto), relating to the common stock of Aerie Pharmaceuticals, Inc., a Delaware corporation, is being filed jointly with the Securities and Exchange Commission pursuant to Rule 13d-1(c) under the Securities
February 11, 2022	SC 13G/A	AERI / Aerie Pharmaceuticals Inc / Flynn James E Passive Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No.
February 9, 2022	SC 13G/A	AERI / Aerie Pharmaceuticals Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 4)* Name of issuer: Aerie Pharmaceuticals Inc. Title of Class of Securities: Common Stock CUSIP Number: 00771V108 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is f
January 25, 2022	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 19, 2022 Aerie Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36152 20-3109565 (State or other jurisdiction of incorporation) (Commi
January 5, 2022	EX-99.1	Disclaimer The information in this presentation regarding Aerie Pharmaceuticals, Inc. (the “Company” or “Aerie”) does not contain all of the information that a potential investor should review before investing in Aerie shares. The descriptions of Aer EX-99.1 2 d275498dex991.htm EX-99.1 Exhibit 99.1 AERIE An Em e r g i n g L e a d e r i n O p h t h a l m o l o g y Ja n u a ry 2 0 2 2 For Investor Use Only 1 Disclaimer The information in this presentation regarding Aerie Pharmaceuticals, Inc. (the “Company” or “Aerie”) does not contain all of the information that a potential investor should review before investing in Aerie shares. The descriptio
January 5, 2022	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 5, 2022 Aerie Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36152 20-3109565 (State or other jurisdiction of incorporation) (Commis
December 16, 2021	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 15, 2021 Aerie Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36152 20-3109565 (State or other jurisdiction of incorporation) (Comm
December 16, 2021	EX-99.1	Aerie Pharmaceuticals Appoints Raj Kannan as Chief Executive Officer An accomplished leader Brings a depth and breadth of commercial, business development, and portfolio strategy experience Exhibit 99.1 Aerie Pharmaceuticals Appoints Raj Kannan as Chief Executive Officer An accomplished leader Brings a depth and breadth of commercial, business development, and portfolio strategy experience Durham, N.C. ? (BUSINESS WIRE) ? December 16, 2021 ? Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company, today announced that Raj Kannan will join the Company as Chief
December 7, 2021	8-K	Regulation FD Disclosure, Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 6, 2021 Aerie Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36152 20-3109565 (State or other jurisdiction of incorporation) (Commi
December 7, 2021	EX-99.1	Aerie Concludes Exclusive License Agreement with Santen for Rhopressa® and Rocklatan® in Europe and Several Other Regions Agreement includes Europe, Commonwealth of Independent States countries, China, India, parts of Latin America and the Oceania co Exhibit 99.1 Aerie Concludes Exclusive License Agreement with Santen for Rhopressa? and Rocklatan? in Europe and Several Other Regions Agreement includes Europe, Commonwealth of Independent States countries, China, India, parts of Latin America and the Oceania countries Durham, NC, December 7, 2021 ? Aerie Pharmaceuticals, Inc. (NASDAQ: AERI, ?Aerie?) announced that Aerie and Santen have entered i
November 10, 2021	CORRESP	*** November 10, 2021 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street N.
November 5, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-3615
November 5, 2021	EX-10.1	Letter Agreement, dated as of September 20, 2021, by and between Aerie Pharmaceuticals, Inc. and Benjamin F. McGraw, III, Pharm.D. EX-10.1 2 aeri93021ex101.htm EX-10.1 Exhibit 10.1 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. [*] INDICATES THAT INFORMATION HAS BEEN REDACTED. AERIE PHARMACEUTICALS, INC. September 20, 2021 Benjamin F. McGraw III, Pharm. D. [*] Dear Ben: On behalf of Aerie Pha
November 4, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 4, 2021 Aerie Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36152 20-3109565 (State or other jurisdiction of incorporation) (Commi
November 4, 2021	EX-99.1	Aerie Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Business Update Third Quarter 2021 Net Revenues of $29.3 Million Increased 46% over Third Quarter 2020 Third Quarter 2021 Net Revenue Per Bottle of $89, up 16% over Third Exhibit 99.1 Aerie Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Business Update Third Quarter 2021 Net Revenues of $29.3 Million Increased 46% over Third Quarter 2020 Third Quarter 2021 Net Revenue Per Bottle of $89, up 16% over Third Quarter 2020 Phase 3 Studies for AR-15512 and AR-1105 Expected to Begin in the First Half of 2022 Conference Call and Webcast Today, Nov
October 21, 2021	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 21, 2021 Aerie Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36152 20-3109565 (State or other jurisdiction of incorporation) (Commi
October 21, 2021	EX-99.1	Important Information The information in this presentation does not contain all of the information that a potential investor should review before investing in Aerie shares. The descriptions of Aerie Pharmaceuticals, Inc. (the “Company” or “Aerie”) in EX-99.1 2 d240839dex991.htm EX-99.1 Building a Global Netarsudil Franchise Tom Mitro President and COO OIS Glaucoma Innovation Summit – October 21, 2021 Summary July 2021 Exhibit 99.1 Important Information The information in this presentation does not contain all of the information that a potential investor should review before investing in Aerie shares. The descriptions of Aerie Pharmaceuticals,
October 20, 2021	8-K/A	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 15, 2021 Aerie Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36152 20-3109565 (State or other jurisdiction of i
October 19, 2021	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 15, 2021 Aerie Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36152 20-3109565 (State or other jurisdiction of incorporation) (Commi
October 12, 2021	EX-99.1	Aerie Pharmaceuticals Announces Positive Phase 3 Topline Results for Netarsudil Ophthalmic Solution 0.02% Clinical Trial in Japan Netarsudil Ophthalmic Solution 0.02% Once Daily Demonstrated Superiority to Ripasudil 0.4% Twice Daily EX-99.1 2 d154401dex991.htm EX-99.1 Exhibit 99.1 Aerie Pharmaceuticals Announces Positive Phase 3 Topline Results for Netarsudil Ophthalmic Solution 0.02% Clinical Trial in Japan Netarsudil Ophthalmic Solution 0.02% Once Daily Demonstrated Superiority to Ripasudil 0.4% Twice Daily Durham, N.C., October 12, 2021 — (BUSINESS WIRE) — Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceut
October 12, 2021	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 12, 2021 Aerie Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36152 20-3109565 (State or other jurisdiction of incorporation) (Commi
October 7, 2021	EX-99.1	Important Information The information in this presentation does not contain all of the information that a potential investor should review before investing in Aerie shares. The descriptions of Aerie Pharmaceuticals, Inc. (the “Company” or “Aerie”) in Exhibit 99.1 PRINT? Drug Delivery Technology: Bringing Small Molecule Chemistry to Retinal Disease Casey Kopczynski, PhD Chief Scientific Officer @ OIS ASRS 2021Exhibit 99.1 PRINT? Drug Delivery Technology: Bringing Small Molecule Chemistry to Retinal Disease Casey Kopczynski, PhD Chief Scientific Officer @ OIS ASRS 2021 Important Information The information in this presentation does not contain a
October 7, 2021	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 7, 2021 Aerie Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36152 20-3109565 (State or other jurisdiction of incorporation) (Commis
September 21, 2021	EX-99.1	Aerie Pharmaceuticals, Inc. Announces the Appointment of Interim Executive Chair and Departure of Chairman and CEO EX-99.1 2 d194484dex991.htm EX-99.1 Exhibit 99.1 Aerie Pharmaceuticals, Inc. Announces the Appointment of Interim Executive Chair and Departure of Chairman and CEO DURHAM, N.C., September 21, 2021—(BUSINESS WIRE)—Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company, today announced that it is executing its succession plan for its long-serving Chairman and CEO and that e
September 21, 2021	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 17, 2021 Aerie Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36152 20-3109565 (State or other jurisdiction of incorporation) (Com
September 15, 2021	EX-99.2	Important Information Any discussion of the potential use or expected success of our product candidates is subject to our regulatory approval. The information in this presentation is current only as of its date and may have changed prior to it being A Phase 2b Study Evaluating the Safety and Efficacy of AR-15512 Ophthalmic Solution for the Treatment of Dry Eye Disease Study AR-15512-CS201 (COMET-1) September 2021 Exhibit 99.
September 15, 2021	EX-99.1	Aerie Pharmaceuticals Announces Novel Dry Eye Product Candidate AR-15512 (TRPM8 Agonist) Ophthalmic Solution Achieved Statistical Significance Over Multiple Symptoms and Signs in Successful Phase 2b Clinical Study for the Treatment of Dry Eye Disease EX-99.1 2 d400726dex991.htm EX-99.1 Exhibit 99.1 Aerie Pharmaceuticals Announces Novel Dry Eye Product Candidate AR-15512 (TRPM8 Agonist) Ophthalmic Solution Achieved Statistical Significance Over Multiple Symptoms and Signs in Successful Phase 2b Clinical Study for the Treatment of Dry Eye Disease AR-15512 (0.003%) BID Advancing to Phase 3; No Treatment-Related Serious or Systemic Adverse Events
September 15, 2021	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 15, 2021 Aerie Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36152 20-3109565 (State or other jurisdiction of incorporation) (Com
September 8, 2021	EX-99.1	For Investor Use Important Information The information in this presentation does not contain all of the information that a potential investor should review before investing in Aerie shares. The descriptions of Aerie Pharmaceuticals, Inc. (the “Compan EX-99.1 2 d127915dex991.htm EX-99.1 Company Overview Investor Presentation September 2021 Exhibit 99.1 For Investor Use Important Information The information in this presentation does not contain all of the information that a potential investor should review before investing in Aerie shares. The descriptions of Aerie Pharmaceuticals, Inc. (the “Company” or “Aerie”) in this presentation are qualifi
September 8, 2021	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 8, 2021 Aerie Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36152 20-3109565 (State or other jurisdiction of incorporation) (Comm
August 16, 2021	SC 13G	AERI / Aerie Pharmaceuticals Inc / Flynn James E Passive Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No.
August 11, 2021	EX-99.1	For Investor Use Important Information The information in this presentation does not contain all of the information that a potential investor should review before investing in Aerie shares. The descriptions of Aerie Pharmaceuticals, Inc. (the “Compan Company Overview Investor Presentation August 2021 Exhibit 99.1 For Investor Use Important Information The information in this presentation does not contain all of the information that a potential investor should review before investing in Aerie shares. The descriptions of Aerie Pharmaceuticals, Inc. (the ?Company? or ?Aerie?) in this presentation are qualified in their entirety by reference to re
August 11, 2021	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2021 Aerie Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36152 20-3109565 (State or other jurisdiction of incorporation) (Commis
August 5, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36152 Aer
August 4, 2021	EX-99.1	Aerie Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Business Update Second Quarter 2021 Net Revenues of $27.2 Million Increased 50.8% over Second Quarter 2020 Second Quarter 2021 Net Revenue Per Bottle of $89, up 14.7% ov EX-99.1 2 aeri-2q21ex991earningsrele.htm EX-99.1 Exhibit 99.1 Aerie Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Business Update Second Quarter 2021 Net Revenues of $27.2 Million Increased 50.8% over Second Quarter 2020 Second Quarter 2021 Net Revenue Per Bottle of $89, up 14.7% over Second Quarter 2020 Phase 2b Topline Results for AR-15512 (COMET-1) Expected in the T
August 4, 2021	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2021 Aerie Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36152 20-3109565 (State or other jurisdiction of incorporation) (Commiss
July 20, 2021	EX-99.1	Important Information The information in this presentation does not contain all of the information that a potential investor should review before investing in Aerie shares. The descriptions of Aerie Pharmaceuticals, Inc. (the “Company” or “Aerie”) in Approaches to Europe: Strategies for Development and Differentiation David A. Hollander, MD, MBA Chief R&D Officer July 20, 2021 Exhibit 99.1 Important Information The information in this presentation does not contain all of the information that a potential investor should review before investing in Aerie shares. The descriptions of Aerie Pharmaceuticals, Inc. (the ?Company? or ?Aerie?) in this pr
July 20, 2021	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 20, 2021 Aerie Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36152 20-3109565 (State or other jurisdiction of incorporation) (Commissi
June 21, 2021	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 21, 2021 Aerie Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36152 20-3109565 (State or other jurisdiction of incorporation) (Commissi
June 21, 2021	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 17, 2021 Aerie Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36152 20-3109565 (State or other jurisdiction of incorporation) (Commissi
June 21, 2021	EX-99.1	For Investor Use Important Information The information in this presentation does not contain all of the information that a potential investor should review before investing in Aerie shares. The descriptions of Aerie Pharmaceuticals, Inc. (the “Compan Company Overview Investor Presentation June 2021 Exhibit 99.1 For Investor Use Important Information The information in this presentation does not contain all of the information that a potential investor should review before investing in Aerie shares. The descriptions of Aerie Pharmaceuticals, Inc. (the ?Company? or ?Aerie?) in this presentation are qualified in their entirety by reference to repo
June 17, 2021	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 17, 2021 Aerie Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36152 20-3109565 (State or other jurisdiction of incorporation) (Commissi
June 17, 2021	EX-99.1	Aerie Pharmaceuticals Completes Enrollment of its first Phase 3 Clinical Trial of Netarsudil Ophthalmic Solution in Japan Topline results expected in the fourth quarter of 2021 Exhibit 99.1 Aerie Pharmaceuticals Completes Enrollment of its first Phase 3 Clinical Trial of Netarsudil Ophthalmic Solution in Japan Topline results expected in the fourth quarter of 2021 Durham, N.C., June 17, 2021 ? Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the tre
May 25, 2021	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 25, 2021 Aerie Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36152 20-3109565 (State or other jurisdiction of incorporation) (Commissio
May 25, 2021	EX-99.1	For Investor Use Important Information The information in this presentation does not contain all of the information that a potential investor should review before investing in Aerie shares. The descriptions of Aerie Pharmaceuticals, Inc. (the “Compan Company Overview Investor Presentation May 2021 Exhibit 99.1 For Investor Use Important Information The information in this presentation does not contain all of the information that a potential investor should review before investing in Aerie shares. The descriptions of Aerie Pharmaceuticals, Inc. (the ?Company? or ?Aerie?) in this presentation are qualified in their entirety by reference to repor
May 24, 2021	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 20, 2021 Aerie Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36152 20-3109565 (State or other jurisdiction of incorporation) (Commissio
May 20, 2021	EX-99.1	For Investor Use Important Information The information in this presentation does not contain all of the information that a potential investor should review before investing in Aerie shares. The descriptions of Aerie Pharmaceuticals, Inc. (the “Compan EX-99.1 2 d142034dex991.htm EX-99.1 Company Overview Investor Presentation May 2021 Exhibit 99.1 For Investor Use Important Information The information in this presentation does not contain all of the information that a potential investor should review before investing in Aerie shares. The descriptions of Aerie Pharmaceuticals, Inc. (the “Company” or “Aerie”) in this presentation are qualified in
May 20, 2021	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 20, 2021 Aerie Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36152 20-3109565 (State or other jurisdiction of incorporation) (Commissio
May 12, 2021	EX-99.1	For Investor Use Important Information The information in this presentation does not contain all of the information that a potential investor should review before investing in Aerie shares. The descriptions of Aerie Pharmaceuticals, Inc. (the “Compan Company Overview Investor Presentation May 2021 Exhibit 99.1 For Investor Use Important Information The information in this presentation does not contain all of the information that a potential investor should review before investing in Aerie shares. The descriptions of Aerie Pharmaceuticals, Inc. (the ?Company? or ?Aerie?) in this presentation are qualified in their entirety by reference to repor
May 12, 2021	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2021 Aerie Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36152 20-3109565 (State or other jurisdiction of incorporation) (Commissio
May 6, 2021	10-Q	Quarterly Report - 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36152 Ae
May 5, 2021	EX-99.1	Aerie Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Business Update First Quarter 2021 Net Revenue Per Bottle of $89, up 11.3% over Fourth Quarter 2020 First Quarter 2021 Net Revenues of $23.0 Million Increased 12.9% over EX-99.1 2 aeri-1q21ex991earningsrele.htm EX-99.1 Exhibit 99.1 Aerie Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Business Update First Quarter 2021 Net Revenue Per Bottle of $89, up 11.3% over Fourth Quarter 2020 First Quarter 2021 Net Revenues of $23.0 Million Increased 12.9% over First Quarter 2020 Significant Progress Made Across the Pipeline Conference Call and Web
May 5, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2021 Aerie Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36152 20-3109565 (State or other jurisdiction of incorporation) (Commission
April 29, 2021	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 29, 2021 Aerie Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36152 20-3109565 (State or other jurisdiction of incorporation) (Commiss
April 29, 2021	EX-99.1	Aerie Pharmaceuticals Completes Enrollment of its Phase 2b Clinical Trial of AR-15512 (TRPM8 Agonist) Ophthalmic Solution for the Treatment of Patients with Dry Eye Disease Topline results expected in the third quarter of 2021 EX-99.1 2 d150919dex991.htm EX-99.1 Exhibit 99.1 Aerie Pharmaceuticals Completes Enrollment of its Phase 2b Clinical Trial of AR-15512 (TRPM8 Agonist) Ophthalmic Solution for the Treatment of Patients with Dry Eye Disease Topline results expected in the third quarter of 2021 Durham, N.C., April 29, 2021 – Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on t
April 28, 2021	EX-99.1	Aerie Pharmaceuticals Announces Presentations at the 2021 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting EX-99.1 2 d139751dex991.htm EX-99.1 Exhibit 99.1 Aerie Pharmaceuticals Announces Presentations at the 2021 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting Durham, N.C., April 28, 2021 – Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment
April 28, 2021	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 28, 2021 Aerie Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36152 20-3109565 (State or other jurisdiction of incorporation) (Commiss
April 27, 2021	DEFA14A	- DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin
April 27, 2021	DEF 14A	Definitive Proxy Statement on Schedule 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin
April 19, 2021	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 19, 2021 Aerie Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36152 20-3109565 (State or other jurisdiction of incorporation) (Commiss
April 19, 2021	EX-99.1	Aerie Pharmaceuticals Receives Marketing Authorisation of Roclanda® 50 micrograms/ml + 200 micrograms/ml Eye Drops, Solution (latanoprost + netarsudil) in Great Britain EX-99.1 2 d147396dex991.htm EX-99.1 Exhibit 99.1 Aerie Pharmaceuticals Receives Marketing Authorisation of Roclanda® 50 micrograms/ml + 200 micrograms/ml Eye Drops, Solution (latanoprost + netarsudil) in Great Britain Durham, N.C., April 19, 2021 – Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-i
April 14, 2021	EX-99.1	For Investor Use Important Information The information in this presentation does not contain all of the information that a potential investor should review before investing in Aerie shares. The descriptions of Aerie Pharmaceuticals, Inc. (the “Compan Company Overview Investor Presentation April 2021 Exhibit 99.1 For Investor Use Important Information The information in this presentation does not contain all of the information that a potential investor should review before investing in Aerie shares. The descriptions of Aerie Pharmaceuticals, Inc. (the ?Company? or ?Aerie?) in this presentation are qualified in their entirety by reference to rep
April 14, 2021	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 14, 2021 Aerie Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36152 20-3109565 (State or other jurisdiction of incorporation) (Commiss
March 30, 2021	EX-99.1	Aerie Pharmaceuticals Announces Publication of Peer-Reviewed Paper Evaluating the Treatment Effect of Netarsudil on Outflow Function in Steroid-Induced Glaucoma EX-99.1 2 d141755dex991.htm EX-99.1 Exhibit 99.1 Aerie Pharmaceuticals Announces Publication of Peer-Reviewed Paper Evaluating the Treatment Effect of Netarsudil on Outflow Function in Steroid-Induced Glaucoma Durham, N.C., March 30, 2021 – Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class
March 30, 2021	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 30, 2021 Aerie Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36152 20-3109565 (State or other jurisdiction of incorporation) (Commiss
March 17, 2021	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 17, 2021 Aerie Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36152 20-3109565 (State or other jurisdiction of incorporation) (Commiss
March 17, 2021	EX-99.1	For Investor Use Important Information The information in this presentation does not contain all of the information that a potential investor should review before investing in Aerie shares. The descriptions of Aerie Pharmaceuticals, Inc. (the “Compan EX-99.1 2 d134224dex991.htm EX-99.1 Company Overview Investor Presentation March 2021 Exhibit 99.1 For Investor Use Important Information The information in this presentation does not contain all of the information that a potential investor should review before investing in Aerie shares. The descriptions of Aerie Pharmaceuticals, Inc. (the “Company” or “Aerie”) in this presentation are qualified i
March 11, 2021	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 11, 2021 Aerie Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36152 20-3109565 (State or other jurisdiction of incorporation) (Commiss
March 11, 2021	EX-99.1	Important Information The information in this presentation does not contain all of the information that a potential investor should review before investing in Aerie shares. The descriptions of Aerie Pharmaceuticals, Inc. (the “Company” or “Aerie”) in EX-99.1 2 d154834dex991.htm EX-99.1 TRPM8: A New Target for the Treatment of Dry Eye David A. Hollander, MD, MBA Chief R&D Officer March 11, 2021 Exhibit 99.1 Important Information The information in this presentation does not contain all of the information that a potential investor should review before investing in Aerie shares. The descriptions of Aerie Pharmaceuticals, Inc. (the “Company” or “A
March 10, 2021	EX-99.1	For Investor Use Important Information The information in this presentation does not contain all of the information that a potential investor should review before investing in Aerie shares. The descriptions of Aerie Pharmaceuticals, Inc. (the “Compan EX-99.1 Company Overview Investor Presentation March 2021 Exhibit 99.1 For Investor Use Important Information The information in this presentation does not contain all of the information that a potential investor should review before investing in Aerie shares. The descriptions of Aerie Pharmaceuticals, Inc. (the “Company” or “Aerie”) in this presentation are qualified in their entirety by referenc
March 10, 2021	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2021 Aerie Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36152 20-3109565 (State or other jurisdiction of incorporation) (Commiss
March 1, 2021	EX-99.1	For Investor Use Important Information The information in this presentation does not contain all of the information that a potential investor should review before investing in Aerie shares. The descriptions of Aerie Pharmaceuticals, Inc. (the “Compan EX-99.1 Company Overview Investor Presentation March 2021 Exhibit 99.1 For Investor Use Important Information The information in this presentation does not contain all of the information that a potential investor should review before investing in Aerie shares. The descriptions of Aerie Pharmaceuticals, Inc. (the “Company” or “Aerie”) in this presentation are qualified in their entirety by referenc
March 1, 2021	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 1, 2021 Aerie Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36152 20-3109565 (State or other jurisdiction of incorporation) (Commissi
February 26, 2021	EX-4.3	Description of the Registrant's Securities. EX-4.3 2 aeriex-43descriptionofther.htm EX-4.3 Exhibit 4.3 Description of Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934 As of December 31, 2020, Aerie Pharmaceuticals, Inc., a Delaware corporation, had one class of securities registered under Section 12 of the Securities Exchange Act of 1934 (the “Exchange Act”): Common Stock, par value $0.001 per share (the “
February 26, 2021	EX-10.32	Collaboration and License Agreement, dated as of October 28, 2020, by and between Aerie Pharmaceuticals Ireland, Ltd. and Santen Pharmaceutical Co., Ltd. (incorporated by reference to Exhibit 10.32 to the Registrant’s Annual Report on Form 10-K (File No. 001-36152) filed on February 26 EXHIBIT 10.32 INFORMATION IN THIS AGREEMENT IDENTIFIED BY ?[***]? IS CONFIDENTIAL AND HAS BEEN EXCLUDED PURSUANT TO ITEM 601(b)(10)(iv) OF REGULATION S-K BECAUSE IT (I) IS NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. COLLABORATION AND LICENSE AGREEMENT by and between AERIE PHARMACEUTICALS IRELAND, LTD. and SANTEN PHARMACEUTICAL CO., LTD. Dated
February 26, 2021	10-K	Annual Report - 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36152 Aerie Pharmaceuticals, Inc.
February 25, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 25, 2021 Aerie Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36152 20-3109565 (State or other jurisdiction of incorporation) (Comm
February 25, 2021	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 25, 2021 Aerie Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36152 20-3109565 (State or other jurisdiction of incorporation) (Comm
February 25, 2021	EX-99.1	For Investor Use Important Information The information in this presentation does not contain all of the information that a potential investor should review before investing in Aerie shares. The descriptions of Aerie Pharmaceuticals, Inc. (the “Compan Axitinib Implant (AR-14034) Overview February 2021 Exhibit 99.1 For Investor Use Important Information The information in this presentation does not contain all of the information that a potential investor should review before investing in Aerie shares. The descriptions of Aerie Pharmaceuticals, Inc. (the ?Company? or ?Aerie?) in this presentation are qualified in their entirety by reference to re
February 25, 2021	EX-99.1	Aerie Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update 2020 Net Revenues of $83.1 Million Increased 19% over 2019 Fourth Quarter Net Revenues of $24.7 Million or $80 Per Bottle New Sustained Rel EX-99.1 2 aeri-4q20earningsreleaseex.htm EX-99.1 Exhibit 99.1 Aerie Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update 2020 Net Revenues of $83.1 Million Increased 19% over 2019 Fourth Quarter Net Revenues of $24.7 Million or $80 Per Bottle New Sustained Release Pan-VEGF Inhibitor Pipeline Candidate Announced Today Conference Call and Webcast T
February 16, 2021	SC 13G/A	December 31, 2020 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) Information Statement Pursuant to Rules 13d-1 and 13d-2 Under the Securities Exchange Act of 1934 (Amendment No. 2 )* Aerie Pharmaceuticals, Inc. (Name of Issuer) Common stock, par value $0.001 per share (Title of Class of Securities) 00771V108 (CUSIP Number) December 31, 2020 Date of Event Which Re
February 10, 2021	SC 13G/A	SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 3)* SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 3)* Name of issuer: Aerie Pharmaceuticals Inc. Title of Class of Securities: Common Stock CUSIP Number: 00771V108 Date of Event Which Requires Filing of this Statement: December 31, 2020 Check the appropriate box to designate the rule pursuant to which this Schedule is f
February 9, 2021	SC 13G	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 (Amendme UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 (Amendment No. )* Aerie Pharmaceutical Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 00771V108 (CUSIP Number) 12/31/2020 (Date of Event Wh
January 19, 2021	8-K	Regulation FD Disclosure, Financial Statements and Exhibits - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 19, 2021 Aerie Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36152 20-3109565 (State or other jurisdiction of incorporation) (Commi
January 19, 2021	EX-99.1	For Investor Use Important Information The information in this presentation does not contain all of the information that a potential investor should review before investing in Aerie shares. The descriptions of Aerie Pharmaceuticals, Inc. (the “Compan EX-99.1 2 d66719dex991.htm EX-99.1 Company Overview Investor Presentation January 2021 Exhibit 99.1 For Investor Use Important Information The information in this presentation does not contain all of the information that a potential investor should review before investing in Aerie shares. The descriptions of Aerie Pharmaceuticals, Inc. (the “Company” or “Aerie”) in this presentation are qualified
January 12, 2021	EX-99.1	For Investor Use Important Information The information in this presentation does not contain all of the information that a potential investor should review before investing in Aerie shares. The descriptions of Aerie Pharmaceuticals, Inc. (the “Compan EX-99.1 2 d107392dex991.htm EX-99.1 Company Overview Investor Presentation January 2021 Exhibit 99.1 For Investor Use Important Information The information in this presentation does not contain all of the information that a potential investor should review before investing in Aerie shares. The descriptions of Aerie Pharmaceuticals, Inc. (the “Company” or “Aerie”) in this presentation are qualified
January 12, 2021	8-K	Regulation FD Disclosure, Financial Statements and Exhibits - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 12, 2021 Aerie Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36152 20-3109565 (State or other jurisdiction of incorporation) (Commi
January 11, 2021	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 11, 2021 Aerie Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36152 20-3109565 (State or other jurisdiction of incorporation) (Commi
January 11, 2021	EX-99.1	Aerie Pharmaceuticals Receives European Commission Approval for Roclanda® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% EX-99.1 Exhibit 99.1 Aerie Pharmaceuticals Receives European Commission Approval for Roclanda® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% Durham, N.C., January 11, 2021 – Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-a
December 15, 2020	EX-99.1	For Investor Use Important Information The information in this presentation does not contain all of the information that a potential investor should review before investing in Aerie shares. The descriptions of Aerie Pharmaceuticals, Inc. (the “Compan EX-99.1 Company Overview Investor Presentation December 2020 Exhibit 99.1 For Investor Use Important Information The information in this presentation does not contain all of the information that a potential investor should review before investing in Aerie shares. The descriptions of Aerie Pharmaceuticals, Inc. (the “Company” or “Aerie”) in this presentation are qualified in their entirety by refer
December 15, 2020	8-K	Regulation FD Disclosure, Financial Statements and Exhibits - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 15, 2020 Aerie Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36152 20-3109565 (State or other jurisdiction of incorporation) (Comm
December 8, 2020	EX-99.1	For Investor Use Important Information The information in this presentation does not contain all of the information that a potential investor should review before investing in Aerie shares. The descriptions of Aerie Pharmaceuticals, Inc. (the “Compan EX-99.1 Company Overview Investor Presentation December 2020 Exhibit 99.1 For Investor Use Important Information The information in this presentation does not contain all of the information that a potential investor should review before investing in Aerie shares. The descriptions of Aerie Pharmaceuticals, Inc. (the “Company” or “Aerie”) in this presentation are qualified in their entirety by refer
December 8, 2020	8-K	Regulation FD Disclosure, Financial Statements and Exhibits - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 8, 2020 Aerie Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36152 20-3109565 (State or other jurisdiction of incorporation) (Commi
November 17, 2020	8-K	Regulation FD Disclosure, Financial Statements and Exhibits - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 17, 2020 Aerie Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36152 20-3109565 (State or other jurisdiction of incorporation) (Comm
November 17, 2020	EX-99.1	For Investor Use Important Information The information in this presentation does not contain all of the information that a potential investor should review before investing in Aerie shares. The descriptions of Aerie Pharmaceuticals, Inc. (the “Compan EX-99.1 Company Overview Investor Presentation November 2020 Exhibit 99.1 For Investor Use Important Information The information in this presentation does not contain all of the information that a potential investor should review before investing in Aerie shares. The descriptions of Aerie Pharmaceuticals, Inc. (the “Company” or “Aerie”) in this presentation are qualified in their entirety by refer
November 13, 2020	8-K	Regulation FD Disclosure, Financial Statements and Exhibits - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2020 Aerie Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36152 20-3109565 (State or other jurisdiction of incorporation) (Comm
November 13, 2020	EX-99.1	Aerie Pharmaceuticals Receives Positive CHMP Opinion for Roclanda® in the European Union -European Commission Decision Anticipated in Approximately Two Months- EX-99.1 Exhibit 99.1 Aerie Pharmaceuticals Receives Positive CHMP Opinion for Roclanda® in the European Union -European Commission Decision Anticipated in Approximately Two Months- Durham, N.C., November 13, 2020 – Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatmen
November 10, 2020	8-K	Regulation FD Disclosure, Financial Statements and Exhibits - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2020 Aerie Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36152 20-3109565 (State or other jurisdiction of incorporation) (Comm
November 10, 2020	EX-99.1	For Investor Use Important Information The information in this presentation does not contain all of the information that a potential investor should review before investing in Aerie shares. The descriptions of Aerie Pharmaceuticals, Inc. (the “Compan EX-99.1 Company Overview Investor Presentation November 2020 Exhibit 99.1 For Investor Use Important Information The information in this presentation does not contain all of the information that a potential investor should review before investing in Aerie shares. The descriptions of Aerie Pharmaceuticals, Inc. (the “Company” or “Aerie”) in this presentation are qualified in their entirety by refer
November 6, 2020	10-Q	Quarterly Report - 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-3615
November 6, 2020	EX-32.2.	Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. Exhibit 32.2 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the filing of the Quarterly Report on Form 10-Q of Aerie Pharmaceuticals, Inc., a Delaware corporation (the “Company”), for the period ended September 30, 2020 (the “Report”), the undersigned, Richard J. Rubino, Chief Financial Officer of the Compan
November 5, 2020	EX-99.1	Aerie Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Business Update Year-to-Date Net Revenues of $58.5 Million Increased 29% over 2019 Third Quarter Net Revenues of $20.1 Million or $77 Per Bottle U.S. Dry Eye Trial Initia EX-99.1 2 aeri-3q20ex991earnings.htm EX-99.1 Exhibit 99.1 Aerie Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Business Update Year-to-Date Net Revenues of $58.5 Million Increased 29% over 2019 Third Quarter Net Revenues of $20.1 Million or $77 Per Bottle U.S. Dry Eye Trial Initiated and Japanese Glaucoma Trial Set to Commence Conference Call and Webcast Today, November
November 5, 2020	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 5, 2020 Aerie Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36152 20-3109565 (State or other jurisdiction of incorporation) (Commi
October 29, 2020	8-K	Regulation FD Disclosure, Financial Statements and Exhibits - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 29, 2020 Aerie Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36152 20-3109565 (State or other jurisdiction of incorporation) (Commi
October 29, 2020	EX-99.1	Aerie Pharmaceuticals Initiates Phase 2b Clinical Trial of AR-15512 (TRPM8 Agonist) Ophthalmic Solution for the Treatment of Patients with Dry Eye Disease -First Patient Dosed in 90-Day Efficacy Trial Named COMET-1- EX-99.1 2 d41216dex991.htm EX-99.1 Exhibit 99.1 Aerie Pharmaceuticals Initiates Phase 2b Clinical Trial of AR-15512 (TRPM8 Agonist) Ophthalmic Solution for the Treatment of Patients with Dry Eye Disease -First Patient Dosed in 90-Day Efficacy Trial Named COMET-1- Durham, N.C., October 29, 2020 – Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discove
October 28, 2020	EX-99.1	Santen and Aerie Conclude Exclusive License Agreement for Rhopressa® and Rocklatan® in Japan and Several Other Asian Countries EX-99.1 Exhibit 99.1 Santen and Aerie Conclude Exclusive License Agreement for Rhopressa® and Rocklatan® in Japan and Several Other Asian Countries Osaka, Japan and Durham, NC, October 28th, 2020 – Santen Pharmaceutical Co., Ltd. (“Santen”) and Aerie Pharmaceuticals, Inc. (NASDAQ: AERI, “Aerie”) announced that Santen and Aerie have entered into an exclusive development and commercialization agreem
October 28, 2020	8-K	Regulation FD Disclosure, Entry into a Material Definitive Agreement, Financial Statements and Exhibits - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 28, 2020 Aerie Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36152 20-3109565 (State or other jurisdiction of incorporation) (Commi
October 6, 2020	8-K	Regulation FD Disclosure, Financial Statements and Exhibits - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 6, 2020 Aerie Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36152 20-3109565 (State or other jurisdiction of incorporation) (Commis
October 6, 2020	EX-99.1	For Investor Use Important Information The information in this presentation does not contain all of the information that a potential investor should review before investing in Aerie shares. The descriptions of Aerie Pharmaceuticals, Inc. (the “Compan EX-99.1 Company Overview Investor Presentation October 2020 Exhibit 99.1 For Investor Use Important Information The information in this presentation does not contain all of the information that a potential investor should review before investing in Aerie shares. The descriptions of Aerie Pharmaceuticals, Inc. (the “Company” or “Aerie”) in this presentation are qualified in their entirety by refere
September 29, 2020	EX-99.1	Aerie Pharmaceuticals Announces Acceptance of Its Investigational New Drug Application for AR-15512 (TRPM8 Agonist) Eye Drop for Dry Eye Disease EX-99.1 Exhibit 99.1 Aerie Pharmaceuticals Announces Acceptance of Its Investigational New Drug Application for AR-15512 (TRPM8 Agonist) Eye Drop for Dry Eye Disease Durham, N.C., September 29, 2020 – Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients
September 29, 2020	8-K	Regulation FD Disclosure, Financial Statements and Exhibits - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 29, 2020 Aerie Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36152 20-3109565 (State or other jurisdiction of incorporation) (Com
September 24, 2020	EX-99.1	Aerie Pharmaceuticals Announces Successful Interim 90-Day Topline Data from its Six-Month Mercury 3 Clinical Trial in Europe - Roclanda® Achieves Non-Inferiority to Ganfort® - - Mercury 3 Performance Exceeds Prior Phase 3 Trials - EX-99.1 Exhibit 99.1 Aerie Pharmaceuticals Announces Successful Interim 90-Day Topline Data from its Six-Month Mercury 3 Clinical Trial in Europe - Roclanda® Achieves Non-Inferiority to Ganfort® - - Mercury 3 Performance Exceeds Prior Phase 3 Trials - Durham, N.C., September 24, 2020 – Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, develo
September 24, 2020	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 24, 2020 Aerie Pharmace UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 24, 2020 Aerie Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36152 20-3109565 (State or other jurisdiction of incorporation) (Com
September 15, 2020	8-K	Regulation FD Disclosure, Financial Statements and Exhibits - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 15, 2020 Aerie Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36152 20-3109565 (State or other jurisdiction of incorporation) (Com
September 15, 2020	EX-99.1	For Investor Use Important Information The information in this presentation does not contain all of the information that a potential investor should review before investing in Aerie shares. The descriptions of Aerie Pharmaceuticals, Inc. (the “Compan EX-99.1 2 d152074dex991.htm EX-99.1 Company Overview Investor Presentation September 2020 Exhibit 99.1 For Investor Use Important Information The information in this presentation does not contain all of the information that a potential investor should review before investing in Aerie shares. The descriptions of Aerie Pharmaceuticals, Inc. (the “Company” or “Aerie”) in this presentation are qualifi
September 15, 2020	EX-99.1	Aerie Pharmaceuticals Announces U.S. Food and Drug Administration Approval of its Athlone, Ireland Facility for Production of Rhopressa® (netarsudil ophthalmic solution) 0.02% EX-99.1 Exhibit 99.1 Aerie Pharmaceuticals Announces U.S. Food and Drug Administration Approval of its Athlone, Ireland Facility for Production of Rhopressa® (netarsudil ophthalmic solution) 0.02% Durham, N.C., September 15, 2020 – Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies
September 15, 2020	8-K	Regulation FD Disclosure, Financial Statements and Exhibits - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 15, 2020 Aerie Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36152 20-3109565 (State or other jurisdiction of incorporation) (Com
September 9, 2020	8-K	Regulation FD Disclosure, Financial Statements and Exhibits - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 9, 2020 Aerie Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36152 20-3109565 (State or other jurisdiction of incorporation) (Comm
September 9, 2020	EX-99.1	For Investor Use Important Information The information in this presentation does not contain all of the information that a potential investor should review before investing in Aerie shares. The descriptions of Aerie Pharmaceuticals, Inc. (the “Compan EX-99.1 Company Overview Investor Presentation September 2020 Exhibit 99.1 For Investor Use Important Information The information in this presentation does not contain all of the information that a potential investor should review before investing in Aerie shares. The descriptions of Aerie Pharmaceuticals, Inc. (the “Company” or “Aerie”) in this presentation are qualified in their entirety by refe
August 12, 2020	EX-99.1	For Investor Use Important Information The information in this presentation does not contain all of the information that a potential investor should review before investing in Aerie shares. The descriptions of Aerie Pharmaceuticals, Inc. (the “Compan EX-99.1 Company Overview Investor Presentation August 2020 Exhibit 99.1 For Investor Use Important Information The information in this presentation does not contain all of the information that a potential investor should review before investing in Aerie shares. The descriptions of Aerie Pharmaceuticals, Inc. (the “Company” or “Aerie”) in this presentation are qualified in their entirety by referen
August 12, 2020	8-K	Regulation FD Disclosure, Financial Statements and Exhibits - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2020 Aerie Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36152 20-3109565 (State or other jurisdiction of incorporation) (Commis
August 7, 2020	10-Q	Quarterly Report - 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36152 Aer
August 6, 2020	EX-99.1	Aerie Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Business Update Year-to-Date Net Revenues of $38.4 Million Increased 44% over 2019 Positive Phase 2 Topline Results for AR-1105 Implant Indicate up to Six-Month Sustaine Exhibit 99.1 Aerie Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Business Update Year-to-Date Net Revenues of $38.4 Million Increased 44% over 2019 Positive Phase 2 Topline Results for AR-1105 Implant Indicate up to Six-Month Sustained Release AR-15512 Trial for Dry Eye, COMET-1, Set to Initiate this Year Conference Call and Webcast Today, August 6th, at 5:00 p.m. ET D
August 6, 2020	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2020 Aerie Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36152 20-3109565 (State or other jurisdiction of incorporation) (Commiss
July 27, 2020	EX-99.1	Aerie Pharmaceuticals Reports Positive Topline Results for AR-1105 (Dexamethasone Intravitreal Implant) Phase 2 Clinical Trial in Patients with Macular Edema Due to Retinal Vein Occlusion EX-99.1 Exhibit 99.1 Aerie Pharmaceuticals Reports Positive Topline Results for AR-1105 (Dexamethasone Intravitreal Implant) Phase 2 Clinical Trial in Patients with Macular Edema Due to Retinal Vein Occlusion Durham, N.C., July 27, 2020 — (BUSINESS WIRE) — Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of
July 27, 2020	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 27, 2020 Aerie Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36152 20-3109565 (State or other jurisdiction of incorporation) (Commissi
July 9, 2020	SC 13G/A	AERI / Aerie Pharmaceuticals, Inc. / Wellington Management Group LLP - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 10 )* Aerie Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 00771V108 (CUSIP Number) June 30, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which th
July 8, 2020	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 8, 2020 Aerie Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36152 20-3109565 (State or other jurisdiction of incorporation) (Commissio
July 8, 2020	EX-99.1	For Investor Use Important Information The information in this presentation does not contain all of the information that a potential investor should review before investing in Aerie shares. The descriptions of Aerie Pharmaceuticals, Inc. (the “Compan EX-99.1 Company Overview Investor Presentation July 2020 Exhibit 99.1 For Investor Use Important Information The information in this presentation does not contain all of the information that a potential investor should review before investing in Aerie shares. The descriptions of Aerie Pharmaceuticals, Inc. (the “Company” or “Aerie”) in this presentation are qualified in their entirety by reference
June 30, 2020	SC 13G/A	AERI / Aerie Pharmaceuticals, Inc. / Flynn James E Passive Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No.
June 17, 2020	EX-99.1	For Investor Use Important Information The information in this presentation does not contain all of the information that a potential investor should review before investing in Aerie shares. The descriptions of Aerie Pharmaceuticals, Inc. (the “Compan EX-99.1 Company Overview Investor Presentation June 2020 Exhibit 99.1 For Investor Use Important Information The information in this presentation does not contain all of the information that a potential investor should review before investing in Aerie shares. The descriptions of Aerie Pharmaceuticals, Inc. (the “Company” or “Aerie”) in this presentation are qualified in their entirety by reference
June 17, 2020	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 17, 2020 Aerie Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36152 20-3109565 (State or other jurisdiction of incorporation) (Commissi
June 15, 2020	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 11, 2020 Aerie Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36152 20-3109565 (State or other jurisdiction of incorporation) (Commissi
June 12, 2020	SC 13G/A	AERI / Aerie Pharmaceuticals, Inc. / Foresite Capital Fund II, L.P. - SC 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1 (b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 (b) (Amendment No. 6)* Aerie Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 00771V108 (CUSIP Number) March 31, 2020 (Date of Event Which Requir
June 11, 2020	EX-99.1	Aerie Pharmaceuticals Appoints Peter J. McDonnell, M.D., to the Company’s Board of Directors EX-99.1 2 d942893dex991.htm EX-99.1 Exhibit 99.1 Aerie Pharmaceuticals Appoints Peter J. McDonnell, M.D., to the Company’s Board of Directors Durham, N.C., June 11, 2020 — (BUSINESS WIRE) — Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-an
June 11, 2020	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 11, 2020 Aerie Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36152 20-3109565 (State or other jurisdiction of incorporation) (Commissi
June 11, 2020	EX-99.1	For Investor Use Important Information The information in this presentation does not contain all of the information that a potential investor should review before investing in Aerie shares. The descriptions of Aerie Pharmaceuticals, Inc. (the “Compan EX-99.1 Company Overview Investor Presentation June 2020 Exhibit 99.1 For Investor Use Important Information The information in this presentation does not contain all of the information that a potential investor should review before investing in Aerie shares. The descriptions of Aerie Pharmaceuticals, Inc. (the “Company” or “Aerie”) in this presentation are qualified in their entirety by reference
June 11, 2020	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 9, 2020 Aerie Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36152 20-3109565 (State or other jurisdiction of incorporation) (Commissio
June 9, 2020	SC 13G/A	AERI / Aerie Pharmaceuticals, Inc. / Wellington Management Group LLP - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 9 )* Aerie Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 00771V108 (CUSIP Number) May 29, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this
May 12, 2020	EX-99.1	For Investor Use Important Information The information in this presentation does not contain all of the information that a potential investor should review before investing in Aerie shares. The descriptions of Aerie Pharmaceuticals, Inc. (the “Compan EX-99.1 Company Overview Investor Presentation May 2020 Exhibit 99.1 For Investor Use Important Information The information in this presentation does not contain all of the information that a potential investor should review before investing in Aerie shares. The descriptions of Aerie Pharmaceuticals, Inc. (the “Company” or “Aerie”) in this presentation are qualified in their entirety by reference
May 12, 2020	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2020 Aerie Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36152 20-3109565 (State or other jurisdiction of incorporation) (Commissio
May 7, 2020	10-Q	Quarterly Report - 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36152 Ae
May 6, 2020	EX-99.1	Aerie Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides Business Update Conference Call and Webcast Today, May 6th, at 5:00 p.m. ET Exhibit 99.1 Aerie Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides Business Update Conference Call and Webcast Today, May 6th, at 5:00 p.m. ET Durham, N.C. - (BUSINESS WIRE) - Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients
May 6, 2020	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2020 Aerie Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36152 20-3109565 (State or other jurisdiction of incorporation) (Commission
April 24, 2020	DEF 14A	- AERIEPROXY2020 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ý Filed by a party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14
April 24, 2020	DEFA14A	- DEFA14A DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
April 14, 2020	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 14, 2020 Aerie Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36152 20-3109565 (State or other jurisdiction of incorporation) (Commiss
April 14, 2020	EX-99.1	For Investor Use Important Information The information in this presentation does not contain all of the information that a potential investor should review before investing in Aerie shares. The descriptions of Aerie Pharmaceuticals, Inc. (the “Compan EX-99.1 Company Overview Investor Presentation April 2020 Exhibit 99.1 For Investor Use Important Information The information in this presentation does not contain all of the information that a potential investor should review before investing in Aerie shares. The descriptions of Aerie Pharmaceuticals, Inc. (the “Company” or “Aerie”) in this presentation are qualified in their entirety by referenc
April 9, 2020	EX-99.1	Aerie Pharmaceuticals Provides 2020 Company and Guidance Update Associated with COVID-19 EX-99.1 Exhibit 99.1 Aerie Pharmaceuticals Provides 2020 Company and Guidance Update Associated with COVID-19 DURHAM, NC, April 09, 2020 – (BUSINESS WIRE) – Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, dry eye, retinal d
April 9, 2020	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 9, 2020 Aerie Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36152 20-3109565 (State or other jurisdiction of incorporation) (Commissi
March 31, 2020	EX-99.1	For Investor Use Important Information The information in this presentation does not contain all of the information that a potential investor should review before investing in Aerie shares. The descriptions of Aerie Pharmaceuticals, Inc. (the “Compan EX-99.1 Company Overview Investor Presentation March 2020 Exhibit 99.1 For Investor Use Important Information The information in this presentation does not contain all of the information that a potential investor should review before investing in Aerie shares. The descriptions of Aerie Pharmaceuticals, Inc. (the “Company” or “Aerie”) in this presentation are qualified in their entirety by referenc
March 31, 2020	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2020 Aerie Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36152 20-3109565 (State or other jurisdiction of incorporation) (Commiss
March 24, 2020	SC 13G	AERI / Aerie Pharmaceuticals, Inc. / Flynn James E Passive Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No.
March 18, 2020	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 18, 2020 Aerie Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36152 20-3109565 (State or other jurisdiction of incorporation) (Commiss
March 18, 2020	EX-99.1	For Investor Use Important Information The information in this presentation does not contain all of the information that a potential investor should review before investing in Aerie shares. The descriptions of Aerie Pharmaceuticals, Inc. (the “Compan EX-99.1 Company Overview Investor Presentation March 2020 Exhibit 99.1 For Investor Use Important Information The information in this presentation does not contain all of the information that a potential investor should review before investing in Aerie shares. The descriptions of Aerie Pharmaceuticals, Inc. (the “Company” or “Aerie”) in this presentation are qualified in their entirety by referenc
March 2, 2020	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 2, 2020 Aerie Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36152 20-3109565 (State or other jurisdiction of incorporation) (Commissi
March 2, 2020	EX-99.1	For Investor Use Important Information The information in this presentation does not contain all of the information that a potential investor should review before investing in Aerie shares. The descriptions of Aerie Pharmaceuticals, Inc. (the “Compan EX-99.1 Company Overview Investor Presentation March 2020 Exhibit 99.1 For Investor Use Important Information The information in this presentation does not contain all of the information that a potential investor should review before investing in Aerie shares. The descriptions of Aerie Pharmaceuticals, Inc. (the “Company” or “Aerie”) in this presentation are qualified in their entirety by referenc
February 24, 2020	EX-10.30	Form of Aerie Pharmaceuticals, Inc. Restricted Stock Unit Award Agreement (incorporated by reference to Exhibit 10.30 to the Registrant’s Annual Report on Form 10-K (File No. 001-36152) filed on February 24, 2020). AERIE PHARMACEUTICALS, INC. SECOND AMENDED & RESTATED OMNIBUS INCENTIVE PLAN FORM OF RESTRICTED STOCK UNIT AWARD AGREEMENT THIS AGREEMENT (this “Agreement”) effective as of the date of grant set forth on the signature page hereto (the “Date of Grant”), is between Aerie Pharmaceuticals, Inc., a Delaware corporation (together with its successors, the “Company”), and the individual whose name is set
February 24, 2020	EX-10.23	Employment Agreement, dated as of October 7, 2019, by and between Aerie Pharmaceuticals, Inc. and David Hollander (incorporated by reference to Exhibit 10.23 to the Registrant’s Annual Report on Form 10-K (File No. 001-36152) filed on February 24, 2020). The XXXXXXXXXXXXX denotes information that has been redacted. EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (the “Agreement”) made as of the 7th of October, 2019 (the “Effective Date”) is by and between Aerie Pharmaceuticals, Inc., a Delaware corporation with principal executive offices at 4301 Emperor Blvd. Suite 400, Durham NC 27703 (the “Company”), and David Hollander, residing at XXXXXXXXXXXX
February 24, 2020	10-K	Annual Report - 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36152 Aerie Pharmaceuticals, Inc.
February 24, 2020	EX-10.31	Amendment to Aerie Pharmaceuticals, Inc. Second Amended & Restated Inducement Award Plan (incorporated by reference to Exhibit 10.31 to the Registrant’s Annual Report on Form 10-K (File No. 001-36152) filed on February 24, 2020). EX-10.31 5 firstamendmenttoaeriep.htm EXHIBIT 10.31 FIRST AMENDMENT OF THE AERIE PHARMACEUTICALS, INC. SECOND AMENDED & RESTATED INDUCEMENT AWARD PLAN THIS FIRST AMENDMENT of the Aerie Pharmaceuticals, Inc. Second Amended & Restated Inducement Award Plan is dated as of December 5, 2019. WHEREAS, the Board of Directors of Aerie Pharmaceuticals, Inc. (the “Company”) has adopted the Aerie Pharmaceuti
February 24, 2020	EX-4.3	Description of the Registrant’s Securities. Exhibit 4.3 Description of Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934 As of December 31, 2019, Aerie Pharmaceuticals, Inc., a Delaware corporation, had one class of securities registered under Section 12 of the Securities Exchange Act of 1934 (the “Exchange Act”): Common Stock, par value $0.001 per share (the “Common Stock”). The following summary includes
February 20, 2020	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 20, 2020 Aerie Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36152 20-3109565 (State or other jurisdiction of incorporation) (Comm
February 20, 2020	EX-99.1	Aerie Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results, Provides 2020 Guidance and Business Update Conference Call and Webcast Today, February 20th, at 5:00 p.m. ET EX-99.1 2 aeri-4q19pressreleaseex991.htm EXHIBIT 99.1 Exhibit 99.1 Aerie Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results, Provides 2020 Guidance and Business Update Conference Call and Webcast Today, February 20th, at 5:00 p.m. ET Durham, N.C. - (BUSINESS WIRE) - Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, de
February 14, 2020	SC 13G/A	AERI / Aerie Pharmaceuticals, Inc. / Partner Fund Management, L.P. - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) Information Statement Pursuant to Rules 13d-1 and 13d-2 Under the Securities Exchange Act of 1934 (Amendment No. 1 )* Aerie Pharmaceuticals, Inc. (Name of Issuer) Common stock, par value $0.001 per share (Title of Class of Securities) 00771V108 (CUSIP Number) December 31, 2019 Date of Event Which Re
February 14, 2020	SC 13G/A	AERI / Aerie Pharmaceuticals, Inc. / HARTFORD MUTUAL FUNDS INC/CT - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 (Amendment No. 1)* Aerie Pharmaceutical Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 00771V108 (CUSIP Number) 12/31/2019 (Date of Event W
February 14, 2020	SC 13G/A	AERI / Aerie Pharmaceuticals, Inc. / Foresite Capital Fund II, L.P. - SC 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1 (b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 (b) (Amendment No. 5)* Aerie Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 00771V108 (CUSIP Number) December 31, 2019 (Date of Event Which Req
February 13, 2020	SC 13G/A	AERI / Aerie Pharmaceuticals, Inc. / Flynn James E Passive Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No.
February 12, 2020	SC 13G/A	AERI / Aerie Pharmaceuticals, Inc. / Adage Capital Partners GP LLC - AERIE PHARMACEUTICALS, INC. Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 5)* Aerie Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 00771V108 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pu
February 12, 2020	SC 13G/A	AERI / Aerie Pharmaceuticals, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 2)* Name of issuer: Aerie Pharmaceuticals Inc Title of Class of Securities: Common Stock CUSIP Number: 00771V108 Date of Event Which Requires Filing of this Statement: December 31, 2019 Check the appropriate box to designate the rule pursuant to which this Schedule is fi
January 28, 2020	SC 13G/A	AERI / Aerie Pharmaceuticals, Inc. / Wellington Management Group LLP - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 8 )* Aerie Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 00771V108 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which
January 21, 2020	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 21, 2020 Aerie Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36152 20-3109565 (State or other jurisdiction of incorporation) (Commi
January 21, 2020	EX-99.1	Aerie Pharmaceuticals Announces U.S. Food and Drug Administration Approval of its Athlone, Ireland Facility for Production of Rocklatan® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% EX-99.1 Exhibit 99.1 Aerie Pharmaceuticals Announces U.S. Food and Drug Administration Approval of its Athlone, Ireland Facility for Production of Rocklatan® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% DURHAM, N.C., January 21, 2020 —(BUSINESS WIRE)— Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercia
January 13, 2020	EX-99.1	For Investor Use Important Information The information in this presentation does not contain all of the information that a potential investor should review before investing in Aerie shares. The descriptions of Aerie Pharmaceuticals, Inc. (the “Compan EX-99.1 Company Overview Investor Presentation January 2020 Exhibit 99.1 For Investor Use Important Information The information in this presentation does not contain all of the information that a potential investor should review before investing in Aerie shares. The descriptions of Aerie Pharmaceuticals, Inc. (the “Company” or “Aerie”) in this presentation are qualified in their entirety by refere
January 13, 2020	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 13, 2020 Aerie Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36152 20-3109565 (State or other jurisdiction of incorporation) (Commi
January 2, 2020	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 2, 2020 Aerie Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36152 20-3109565 (State or other jurisdiction of incorporation) (Commis
January 2, 2020	EX-99.1	Aerie Pharmaceuticals Announces Acceptance for Review of the Roclanda® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% Marketing Authorisation Application in Europe EX-99.1 Exhibit 99.1 Aerie Pharmaceuticals Announces Acceptance for Review of the Roclanda® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% Marketing Authorisation Application in Europe DURHAM, N.C., January 2, 2020 —(BUSINESS WIRE)— Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-

AERI / Aerie Pharmaceuticals Inc - Pengajuan SECLaporan Tahunan, Pernyataan Proksi

Mga Batayang Estadistika

SEC Filings

SEC Filings (Chronological Order)